Archives
382 / 652
Premium Portfolio
Optionalysis: Writing Options Fraught With IV Rise Danger, But Risk/Reward Favourable
This is a post for Capital Mind Premium subscribers, sent on 02 May 2014. You might think the Vix is high, at 33. Or that implied volatilities look very high. ...
Stocks
Whatever Will Be, Will Be 20% Up!
In December 2013, I was looking at this stock: At the point of the purple arrow, the question was: would I buy? The answer, at the time, was: Why not? All time ...
Premium Portfolio
Optionalysis: Nifty Looks Poised For A Trend Change
This is a Capital Mind Premium subscriber post, sent on 30 May 2014. Be Careful. Option trading is largely focussed on the Nifty. The Nifty has suddenly turned ...
Premium
Premium: Webinar Recording is Up; Bonus Charts of Smallcap Outperformance
This is a post for Capital Mind Premium subscribers. The recording for Saturday’s webinar is at: ...
Charts & Analysis
Monthly Moves: April Stagnates, May is Traditionally Volatile
In Monthly Moves we notice that the Nifty has slowed down, with April being a stagnating month, giving a -0.1% return on the Nifty and +0.1% on the Sensex. ...
General
The Negatives of the Reliance My Gold Plan
There’s a new investment idea in town. The Reliance My Gold Plan allows you to buy gold through “Daily averaging”, by taking a (minimum of) Rs. 1,000 ...
Stocks
Sun-Baxy Deal Dinged For Insider Trading
The SunPharma-Ranbaxy deal has hit a little snag. The Andhra Pradesh High Court has temporarily stalled the merger, asking SEBI and stock exchanges not to ...
Charts & Analysis
Nifty EPS growth at 7%, P/E at 19
After many results have come in, the Nifty EPS (earnings per share) calculated on a standalone basis is at Rs. 355. This has moved from a base of Rs. 209 five ...
Premium
Strides Up 12% on FDA Approval, Portfolio Gains
This is a Capital Mind Premium post, sent on April 26, 2014. Strides Arcolab has seen a surge in its stock price on news that the FDA continues its approvalfor ...
Premium